Ipsen announced that the FDA has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment...
Ipsen has announced that Somatuline Depot (lanreotide) Injection 120 mg was approved by the FDA for the treatment of adult...
Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GA Depot 40 mg from the FDA
Mapi Pharma announced positive top-line results from the GA Depot (a long acting glatiramer acetate) Phase III clinical trial assessing the efficacy, safety and tolerability of a once monthly GA Depot 40 mg compared to placebo in relapsing forms of multiple sclerosis (RMS) patients
Ipsen Biopharmaceuticals announced that Endocrine Practice has published Phase III clinical trial results examining the efficacy and safety of Somatuline...